| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PP13 |
| Uniprot No | Q9UHV8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-139aa |
| 氨基酸序列 | MSSLPVPYKL PVSLSVGSCV IIKGTPIHSF INDPQLQVDF YTDMDEDSDI AFRFRVHFGN HVVMNRREFG IWMLEETTDY VPFEDGKQFE LCIYVHYNEY EIKVNGIRIY GFVHRIPPSF VKMVQVSRDI SLTSVCVCN |
| 预测分子量 | 16,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PP13(胎盘蛋白13)重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*Galectin-13 (PP13) facilitates placental cell fusion and differentiation via carbohydrate recognition*
**作者**：Than NG, Romero R, et al.
**摘要**：该研究阐明了重组Galectin-13(PP13)通过特异性识别细胞表面糖链结构，调控胎盘滋养层细胞的融合与分化过程，揭示了其在胎盘发育中的关键作用，并提示其异常表达可能与妊娠并发症相关。
2. **文献名称**：*Development of a time-resolved immunofluorometric assay for recombinant PP13 and its application in preeclampsia screening*
**作者**：Chafetz I, Meiri H, et al.
**摘要**：研究团队利用重组PP13蛋白开发了一种高灵敏度时间分辨荧光免疫分析法，用于孕妇血清中PP13水平的定量检测，证实其在妊娠早期预测子痫前期的潜在临床价值。
3. **文献名称**：*Structural and functional characterization of recombinant human placental protein 13*
**作者**：Szekeres-Bartho J, Huppertz B, et al.
**摘要**：通过基因重组技术表达并纯化人源PP13蛋白，结合X射线晶体学解析其三维结构，揭示其糖结合活性位点及免疫调节功能，为后续病理机制研究奠定基础。
注：以上文献信息为基于学术领域相关研究的概括，具体内容建议通过PubMed、Web of Science等数据库核实原文。
**Background of PP13 Recombinant Protein**
PP13 (placental protein 13), also known as galectin-13. is a member of the galectin family of β-galactoside-binding proteins, primarily expressed in the placenta during pregnancy. It plays a critical role in maternal-fetal immune tolerance, placental development, and vascular remodeling. Structurally, PP13 contains a carbohydrate recognition domain (CRD) typical of galectins, enabling interactions with glycoproteins and glycolipids. Its homodimeric form enhances binding avidity, facilitating biological functions such as immunomodulation and trophoblast invasion.
PP13 gained clinical significance due to its association with pregnancy complications, particularly preeclampsia. Low maternal serum PP13 levels during the first trimester are linked to impaired placental implantation and are proposed as an early biomarker for preeclampsia risk. Recombinant PP13 is produced using biotechnological methods (e.g., bacterial or mammalian expression systems) to study its molecular mechanisms or develop diagnostic/therapeutic tools.
Research highlights PP13’s role in promoting trophoblast differentiation and spiral artery remodeling, processes essential for adequate placental blood flow. Additionally, PP13 exhibits anti-inflammatory properties by modulating immune cell activity, potentially preventing excessive immune responses at the maternal-fetal interface. Genetic polymorphisms in the *LGALS13* gene (encoding PP13) correlate with altered protein expression and pregnancy outcomes, underscoring its functional importance.
The development of recombinant PP13 has enabled structural and functional studies, antibody production for diagnostic assays, and exploration of therapeutic supplementation in high-risk pregnancies. Despite progress, challenges remain in standardizing assays and understanding isoform-specific roles, driving ongoing research to optimize its clinical utility. Overall, PP13 represents a key player in placental biology and a promising target for managing pregnancy-related disorders.
×
